Deerfield Management Company has launched Deerfield Private Design Fund III, an investment fund designed to provide flexible private financing to healthcare companies.
The fund has approximately USD1.6bn in committed capital.
“Deerfield is proud to play a leading role in advancing innovation in the development and delivery of healthcare products and services through investment, information and philanthropy. Few other industries can have such a profound impact on the quality and length of life,” says James Flynn, managing partner at Deerfield.
The mission of Deerfield Private Design III is to advance all aspects of medicine and human health. Like Deerfield’s two previous private funds, the new fund will invest in all segments of the healthcare market including biotechnology, pharmaceuticals, medical devices, healthcare services, and animal health. It will employ a full range of financing structures including equity, debt, royalty interests, joint ventures and other structured financing alternatives. The fund is designed to provide customised solutions to private and public companies at all stages of development, ranging from early-stage start-ups to established industry leaders.
In addition to managing approximately USD3bn in public healthcare investments, Deerfield has raised and successfully invested two prior private healthcare funds. Deerfield Private Design I invested in excess of USD500m, and Deerfield Private Design II is in the final stages of committing approximately USD1bn. Each fund has supported a select group of partner companies focused on advancing healthcare.
